China to accelerate its drug approval system to cut down lengthy delays
Date: 2017-10-09   Author: Ojaswita Kutepatil  Category: #news

China is set to speed up its approval system for medicines and also plans to accept data from clinical trials that are carried out overseas. Reportedly, these changes in the drug approval system will cut down extensive delays in approval processes for new treatment, by several years.

The move, announced by China’s cabinet, is likely to open huge opportunities for local drug innovators and overseas drug makers who repeatedly face lengthy time gaps until the new medicines enter the market. China’s initiative is likely to help the country bridge an innovation gap with the developed international pharmaceutical market.

The announcement comes on the heels of the demand for new therapies that has been significantly increasing in China due to the rising prevalence of chronic diseases such as diabetes and cancer. Additionally, the country’s growing geriatric population is also expected to boost the drug industry. These factors, cite experts, may help support the shift from conventional drugs to more innovative medicines and equipment in the region.

Faster drug approvals are expected to provide a major thrust to the blockbuster drugs from multinationals like AstraZeneca Plc., Pfizer Inc., and GlaxoSmithKline Plc., that are looking forward to penetrating deeper into the China market. For the record, China is world’s second largest pharmaceutical market having expended USD 116.7 billion in 2016, after the United States.  

Experts speculate this move to improve patients’ access to new treatments and medicines, thereby increasing revenues of pharmaceutical companies. It is also likely to help the Chinese industry select its players who are fittest for survival, those who would uplift the overall competitiveness.

According to the document that reforms the drug approval system, the Government of China will relax the processes for research institutions to conduct clinical trials and also establish a compulsory licensing system for clinically needed drugs & equipment. The government is also expected to foresee new set of rules that will protect patents.

About Author

Ojaswita Kutepatil

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, worked as a BDE and Technical Engineer before switching her profession to content writing. Currently, she works at AlgosOnline. as an Associate Content writer, where she pens down write-ups pertaining to the ...

Read More

More from Ojaswita

Post Recommendents

Alibaba prioritizes SEA expansion, pours in USD 2bn more in Lazada
Author: Dhananjay Punekar

Alibaba Group Holding Limited, a Chinese eCommerce & retail firm, is expected to provide an additional investment worth USD 2 billion to Lazada Group SA, an eCommerce firm headquartered in Singapore.  Incident...

Grofers secures USD 61.6 million in funding round led by SoftBank
Author: Dhananjay Punekar

Grofers, an India-based online grocery delivery service, has received funds worth USD 61.6 million from SoftBank Group via its initial fund-raising round. Incidentally, the round also witnessed the participation of Apo...

Mayne Pharma Group launches a generic alternative to Monodox in U.S.
Author: Sunil Hebbalkar

Mayne Pharma Group, the Australia-headquartered drug delivery conglomerate, has recently announced the launch of doxycycline monohydrate IR capsules in the United States. Reportedly, the scarcely launched drug is a gen...